Acute myeloid leukemia (AML), the most common acute leukemia, remains difficult to treat.

Drugs used for solid cancers or inflammatory diseases can sometimes be at least partially effective in treating certain AMLs (“therapeutic repositioning”), but they must be used in combination to provide patients with clinical benefit.

Furthermore, the use of these therapeutic strategies cannot be guided by a simple blood laboratory test.

Conversely, it is now possible, using a leukemia sample, to test the efficacy of drug combinations in vitro in each patient in order to identify potentially effective drug combinations for a given leukemia.

This is referred to as pharmacological screening and personalized treatment.

Our project is based on an innovative pharmacological screening method and aims first to establish the feasibility of this real-time approach for patients with relapsed AML.

It also aims to identify innovative drug combinations that are active in a sufficient number of patients in vitro to be the subject of a clinical trial led by the Leukemia Institute.